

Petr Szturz

MD, PhD

Petr Szturz is a medical oncologist at the Lausanne University Hospital in Switzerland. After receiving his medical training at the Masaryk University in Brno, Czechia and Medical University of Vienna, Austria, he participated in several fellowships organized by the ESMO, including a one-year translational research fellowship at the Bichat-Beaujon University Hospital in Paris, France.

With more than 120 peer-reviewed articles, of which on over 50 he was the first author, Dr. Szturz holds special interest in the areas of head and neck cancer, translational research, gastrointestinal oncology, and very rare diseases.

His publications have appeared in the Lancet, Journal of Clinical Oncology, European Journal of Cancer, and other journals and have been cited in major clinical practice recommendations, including guidelines of the NCCN, ESMO, American Radium Society, and ASCO. He is the first author of a prognostic factor analysis and long-term results of the practice-changing TAX 323 (EORTC 24971) trial.

Dr. Szturz has been an invited speaker at several national and international conferences and a member of advisory committees of the ECHNO-ICHNO and ESMO congresses. He has been involved in clinical and translational studies, also participating in editorial work for several

journals such as Frontiers in Oncology and Cancers. Dr. Szturz was granted the award for the Best fellowship project from the ESMO and the Young Investigators Award from the German, Austrian, and Swiss Societies for Haematology and Oncology (DGHO).

Dr. Szturz joined the EORTC in 2018, year in which the Young Investigators Program of the EORTC Head and Neck Cancer Group was launched. Later, he was elected the Young and Early Career Investigator Representative of this group, and in 2022, he was appointed on the EORTC Board.

